Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: yosi s who wrote (602)	4/17/1998 5:05:00 PM
From: Cacaito	Read Replies (1) of 1491

Yosi s: The care of patients in well designed trials is usually above the standard of care due to the strong and detail attention to protocols and in this case the high quality of the institution doing the clinical study, this could explained "if there is a much lower mortality in the placebo group". This is the reason that I chose to calculate the probable outcomes on the low side (it also protect me from my own enthusiasm). Even if the placebo group does have a low mortality it will not invalidate the purpose of the phase II study and it will confirm the need for a definitive phase III study. Historical controls (data from the same type of patients in non research conditions) could provide additional justification for a phase III study. It is disturbing that many companies will go ahead with pre-selected low risk populations, sometimes entirely by design. I agree with you that the avoidance of "easy" patients is a plus for the PARS study. The dexanabinol study subjects are sick to the point of 12.5% death rate. This is a sign of true clinical and scientific commitment from Pharmos.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next